ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 826

Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death

Meifang Wu1, Eric Yen 2 and Ram Raj Singh 2, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2UCLA, Los Angeles

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, death and morbidity and mortality

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Almost every organ system can be affected by primary immune-mediated diseases characterized by inflammation and therapeutic response to immune-suppressive or anti-inflammatory drugs. These diseases can be collectively referred to as immune-mediated inflammatory diseases (IMID). Many rheumatic diseases can be categorized as IMIDs. Since IMIDs are purported to have shared pathogenic mechanisms, it would be important to understand their burden of disease together. Our goals are to determine 1) the burden of IMID deaths relative to the leading causes of death published by the Centers for Disease Control and Prevention (CDC) and 2) the mortality trends of top 15 individual IMIDs.

Methods: We compiled 43 IMIDs with a reported prevalence of >1 per 100,000 population, and obtained death counts for each of them using the CDC-WONDER database. We then calculated their crude death rates, pooled death counts of the 15 IMIDs with the highest crude death rates, and ranked the pooled IMID death counts among the CDC’s official leading-causes-of-death ranklist for eleven age groups. Next, we calculated the annual age-standardized mortality rate (ASMR) for the top 15 individual IMIDs from 1999 to 2017. Lastly, we performed joinpoint trend analysis of the annual ASMRs for these 15 IMIDs.

Results: 371,154 deaths were attributed to the top 15 IMIDs in 5 years from 2013 to 2017. Of these deaths, IMIDs were recorded as the underlying cause in 202,430 deaths and as the contributing cause in 168,724 deaths. These IMID deaths (underlying + contributing) ranked 6th to 9th for all age groups among the leading causes of death. When only the underlying cause of death was considered, IMID ranked among the top 15 for all age groups and 7th to 9th in 15 to 64 year age groups. Among IMIDs, primary interstitial lung disease, multiple sclerosis, and type 1 diabetes had the highest ASMRs in 2017 followed by rheumatic diseases including rheumatoid arthritis, lupus, systemic sclerosis, and systemic vasculitis, which ranked in the top 10. Joinpoint trend analysis showed that annual mortality rates for most IMIDs including rheumatoid arthritis, lupus, systemic sclerosis, systemic vasculitis, type 1 diabetes, myocarditis, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura have decreased from 1999 to 2017, but have increased or unchanged for a few IMIDs including primary interstitial lung disease, multiple sclerosis, and myasthenia gravis.

Conclusion: Ranking of IMID among the top ten leading causes of death emphasizes the high burden of diseases characterized by inflammation. These data further highlight that IMID is a major public health problem. Similar to various forms of cancer, various IMIDs should be considered as a collective disease entity. The recognition of IMID as a leading cause of death may influence healthcare prioritization and research funding, which may help to reduce their disease burden.


Disclosure: M. Wu, None; E. Yen, None; R. Singh, None.

To cite this abstract in AMA style:

Wu M, Yen E, Singh R. Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/immune-mediated-inflammatory-diseases-imid-collectively-rank-among-the-leading-causes-of-death/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-mediated-inflammatory-diseases-imid-collectively-rank-among-the-leading-causes-of-death/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology